Epub 2019 Sep 30.

Trimaran trial asthma. Data from 2 RCTs n2592 showed improvements in forced expiratory volume in 1s FEV1. In the TRIMARAN trial 579 patients received a medium strength dose 100 micrograms of the ICS beclometasone dipropionate BDP 6 micrograms of the LABA formoterol fumerate FF and 10 micrograms of the LAMA glycopyrronium G. Johann Christian Virchow MD1 Prof.

Dave Singh MD Sandrine Corre MSc6 Florence Zuccaro. TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS LABA TRIMARAN The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Virchow JC Kuna P Paggiaro P Papi A Singh D Corre S Zuccaro F Vele A Kots M Georges G Petruzzelli S Canonica GW.

Listing a study does not mean it has been evaluated by the US. 2 Single inhaler extrafine triple therapy in uncontrolled asthma. Trial design and participants e full design and inclusionexclusion criteria of TRI-MARAN and TRIGGER have been previously pub-lished 14.

About the TRIMARAN and TRIGGER studies TRIMARAN and TRIGER are two randomised parallel-group double-blind active-controlled studies. Single inhaler extrafine triple therapy in uncontrolled asthma TRIMARAN and TRIGGER. Pierluigi Paggiaro MD 6 Prof.

Single inhaler extrafine triple therapy in uncontrolled asthma TRIMARAN and TRIGGER. TRIMARAN and TRIGGER were double-blind 52-week studies comparing BDPFFG with BDPFF TRIMARAN medium-dose ICS. 127 mL respectively p0008 2.

Two randomised double-blind 3 parallel group controlled trials TRIMARAN and TRIGGER 4 Authors 5 Prof. TRIGGER high-dose in adults with uncontrolled asthma Asthma Control Questionnaire-7 15 pre-bronchodilator FEV 1. Two double-blind parallel-group randomised controlled phase 3 trials.